BACKGROUND: Alkylating agents are commonly used in the treatment of childhood malignant gliomas. Overexpression of O(6)-methylguanine-DNA methyltransferase (MGMT) constitutes an important mechanism for resistance to such agents, and MGMT status has been associated with outcome in several recent trials. Deficiency in mismatch repair (MMR) function has been implicated in preclinical studies as an additional potential mechanism of resistance to methylating agents, such as temozolomide, independent of tumor MGMT status. However, the frequency of this abnormality as a clinical resistance mechanism in childhood malignant gliomas has not been well characterized. METHODS: To address this issue, we examined the frequency of microsatellite instability (MSI), a marker of defective MMR, in a series of 68 tumors, derived from newly diagnosed patients treated on the Children's Cancer Group 945 study, and the Children's Oncology Group ACNS0126 and 0423 studies. MSI was assessed using a panel of six microsatellite markers, including BAT-25, BAT-26, CAT-25, D2S123, D5S346, and D17S250. MGMT immunoreactivity was assessed in parallel to allow comparison of the relative incidence of MGMT overexpression and MSI. RESULTS: Only three tumors had high-level MSI involving three or more markers; the remainder had no MSI at any of the loci examined. These children did not have unusual features in terms of their outcome. In contrast to the infrequency of MSI, 25 tumors (37%) exhibited MGMT overexpression as assessed by immunohistochemistry. None of the tumors with MSI exhibited overexpression of MGMT. CONCLUSION: MMR deficiency is an infrequent contributor to initial alkylator resistance in children with malignant gliomas.
BACKGROUND: Alkylating agents are commonly used in the treatment of childhood malignant gliomas. Overexpression of O(6)-methylguanine-DNA methyltransferase (MGMT) constitutes an important mechanism for resistance to such agents, and MGMT status has been associated with outcome in several recent trials. Deficiency in mismatch repair (MMR) function has been implicated in preclinical studies as an additional potential mechanism of resistance to methylating agents, such as temozolomide, independent of tumorMGMT status. However, the frequency of this abnormality as a clinical resistance mechanism in childhood malignant gliomas has not been well characterized. METHODS: To address this issue, we examined the frequency of microsatellite instability (MSI), a marker of defective MMR, in a series of 68 tumors, derived from newly diagnosed patients treated on the Children's Cancer Group 945 study, and the Children's Oncology Group ACNS0126 and 0423 studies. MSI was assessed using a panel of six microsatellite markers, including BAT-25, BAT-26, CAT-25, D2S123, D5S346, and D17S250. MGMT immunoreactivity was assessed in parallel to allow comparison of the relative incidence of MGMT overexpression and MSI. RESULTS: Only three tumors had high-level MSI involving three or more markers; the remainder had no MSI at any of the loci examined. These children did not have unusual features in terms of their outcome. In contrast to the infrequency of MSI, 25 tumors (37%) exhibited MGMT overexpression as assessed by immunohistochemistry. None of the tumors with MSI exhibited overexpression of MGMT. CONCLUSION:MMR deficiency is an infrequent contributor to initial alkylator resistance in children with malignant gliomas.
Authors: Carme Balaña; Jose Luis Ramirez; Miquel Taron; Yannis Roussos; Aurelio Ariza; Rosa Ballester; Carme Sarries; Pedro Mendez; Jose Javier Sanchez; Rafael Rosell Journal: Clin Cancer Res Date: 2003-04 Impact factor: 12.531
Authors: D S Middlemas; C F Stewart; M N Kirstein; C Poquette; H S Friedman; P J Houghton; T P Brent Journal: Clin Cancer Res Date: 2000-03 Impact factor: 12.531
Authors: M Kanamori; H Kon; T Nobukuni; S Nomura; K Sugano; S Mashiyama; T Kumabe; T Yoshimoto; M Meuth; T Sekiya; Y Murakami Journal: Oncogene Date: 2000-03-16 Impact factor: 9.867
Authors: M Esteller; J Garcia-Foncillas; E Andion; S N Goodman; O F Hidalgo; V Vanaclocha; S B Baylin; J G Herman Journal: N Engl J Med Date: 2000-11-09 Impact factor: 91.245
Authors: Ian F Pollack; Sydney D Finkelstein; Jeffrey Woods; Judith Burnham; Emiko J Holmes; Ronald L Hamilton; Allan J Yates; James M Boyett; Jonathan L Finlay; Richard Sposto Journal: N Engl J Med Date: 2002-02-07 Impact factor: 91.245
Authors: M Alonso; R Hamelin; M Kim; K Porwancher; T Sung; P Parhar; D C Miller; E W Newcomb Journal: Cancer Res Date: 2001-03-01 Impact factor: 12.701
Authors: Ian F Pollack; James M Boyett; Allan J Yates; Peter C Burger; Floyd H Gilles; Richard L Davis; Jonathan L Finlay Journal: Neuro Oncol Date: 2003-07 Impact factor: 12.300
Authors: Johannes E Wolff; Michael E Rytting; Tribhawan S Vats; Peter E Zage; Joann L Ater; Shiao Woo; John Kuttesch; Leena Ketonen; Anita Mahajan Journal: J Neurooncol Date: 2011-08-20 Impact factor: 4.130
Authors: Stephen T Keir; John M Maris; C Patrick Reynolds; Min H Kang; E Anders Kolb; Richard Gorlick; Richard Lock; Hernan Carol; Christopher L Morton; Jianrong Wu; Raushan T Kurmasheva; Peter J Houghton; Malcolm A Smith Journal: Pediatr Blood Cancer Date: 2013-01-17 Impact factor: 3.167
Authors: Regina I Jakacki; Kenneth J Cohen; Allen Buxton; Mark D Krailo; Peter C Burger; Marc K Rosenblum; Daniel J Brat; Ronald L Hamilton; Sandrah P Eckel; Tianni Zhou; Robert S Lavey; Ian F Pollack Journal: Neuro Oncol Date: 2016-03-22 Impact factor: 12.300
Authors: A O von Bueren; M D Bacolod; C Hagel; K Heinimann; A Fedier; U Kordes; T Pietsch; J Koster; M A Grotzer; H S Friedman; G Marra; M Kool; S Rutkowski Journal: Br J Cancer Date: 2012-09-13 Impact factor: 7.640
Authors: Marta Viana-Pereira; Alicia Lee; Sergey Popov; Dorine A Bax; Safa Al-Sarraj; Leslie R Bridges; João N Stávale; Darren Hargrave; Chris Jones; Rui M Reis Journal: PLoS One Date: 2011-05-26 Impact factor: 3.240